Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04497987 · ClinicalTrials.gov registry record · Phase 3

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

A Phase 3 study of COVID-19 and Sars-CoV2, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
1,180
Enrollment target
20
Study locations

NCT04497987 is a Phase 3 study of COVID-19 and Sars-CoV2 that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,180 participants, below the 55,209-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04497987, a Phase 3 study of COVID-19 and Sars-CoV2, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
1,180 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19). Facility staff and residents in contracted skilled nursing and assisted living facility networks with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. Participation could last up to 25 weeks and may include up to 19 visits.

Conditions Studied

COVID-19 Sars-CoV2

Interventions

  • DRUG Placebo
  • DRUG Bamlanivimab
  • DRUG Etesevimab

Study Locations (20)

California

  • Care Access Research LLC - Huntington Beach
  • Alta Bates SMC - Oakland

Louisiana

  • Care Access Rch Lake Charles - Lake Charles
  • Tulane University School of Medicine - New Orleans

Mississippi

  • Care Access - Jackson
  • University of Mississippi Medical Center - Jackson

Alabama

  • Unv of AL Sch of Med Div of Infectious Diseases - Birmingham

Arizona

  • Care Access Research - Phoenix

Arkansas

  • Allergy and Asthma Clin of NW Ark - Bentonville

Colorado

  • University of Colorado-Anschultz Medical Campus - Aurora

Florida

  • NIAID - Miami

Trial Details

FieldValue
Enrollment Target 1,180 participants
Start Date 2020-08-02
Est. Completion 2021-05-20
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04497987

The ClinicalTrials.gov registry entry for NCT04497987 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,209-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04497987 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Louisiana, Mississippi.

Frequently Asked Questions

What is clinical trial NCT04497987 about?

NCT04497987 is a clinical study titled "A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff". The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19). Facility staff and residents in contracted skilled nursing and assisted living facility ...

What is the current status of trial NCT04497987?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,180 participants. The study started on 2020-08-02. Estimated completion is 2021-05-20.

What conditions does trial NCT04497987 study?

This clinical trial studies the following conditions: COVID-19, Sars-CoV2.

What interventions are being tested in trial NCT04497987?

The interventions under investigation include: Placebo (DRUG), Bamlanivimab (DRUG), Etesevimab (DRUG).

Who is sponsoring clinical trial NCT04497987?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04497987 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Sars-CoV2

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.